Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20220809055645N7
IRCT20220809055645N7
Recruiting
Phase 3

Investigating the effect of Empagliflozin on outcomes of patients with myocardial infarction undergoing primary Percutaneous coronary intervention (PCI):a randomized double-blind clinical trial with placebo

Rasht University of Medical Sciences0 sites54 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Rasht University of Medical Sciences
Enrollment
54
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Rasht University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • •Patients with ST segment elevation myocardial infarction (STEMI) undergoing successful Primary PCI without complications
  • •Based on New York Heart Association (NYHA) functional class I,II,III
  • •Informed consent for participation in study

Exclusion Criteria

  • •Failure of primary PCI
  • •Empagliflozin contraindications
  • •Valvular heart disease with moderate and higher severity
  • •Patients who need hemodynamic support during hospitalization
  • •Not willing to continue participation in study
  • •Receiving drugs ,eg Non\-steroidal anti\-inflammatory drugs (NSAIDs) which can not be denied

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 3
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shunt
IRCT20120520009801N11Mashhad University of Medical Sciences44
Completed
Phase 1
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8
IRCT20150706023084N18Islamic Azad University30
Recruiting
Phase 3
Evaluation of the effectiveness of Empagliflozin on metabolic factors and liver function tests
IRCT20191209045671N3Semnan University of Medical Sciences60
Recruiting
Phase 2
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after heart surgeryAtrial fibrillation after heart surgery.Paroxysmal atrial fibrillation
IRCT20120520009801N9Mashhad University of Medical Sciences160
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02
IRCT20220902055858N1Shahre-kord University of Medical Sciences90